Added to YB: 2026-03-30
Pitch date: 2026-03-26
HROW [bullish]
Harrow, Inc.
-4%
current return
Author Info
No bio for this author
Company Info
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States.
Market Cap
$1.4B
Pitch Price
$35.24
Price Target
65.00 (+92%)
Dividend
N/A
EV/EBITDA
30.43
P/E
-260.02
EV/Sales
5.62
Sector
Pharmaceuticals
Category
growth
Harrow Inc. - Quietly building an Eye Care Empire!
HROW: Ophthalmic pharma building largest US branded portfolio. VEVYE (dry eye) $88.7M in 2025 (+216% YoY), IHEEZO (anesthesia) +57%, TRIESENCE targeting $100M. Q4 rev $89.1M (+33%), FY25 $272.3M (+36%), adj EBITDA $61.9M (+54%). 2026 guide $350-365M rev, $95-105M EBITDA. Launching BYQLOVI (Q2), BYOOVIZ/OPUVIZ biosimilars (anti-VEGF, $8B+ market). G-MELT NDA 2027. $65 PT (+86% upside). Risks: execution, payer coverage, 539% debt/equity, competitive dry eye market.
Read full article (11 min)